EMA — authorised 15 November 2021
- Marketing authorisation holder: BIOGEN NETHERLANDS B.V.
- Status: approved
🇪🇺 Vumerity in European Union
EMA authorised Vumerity on 15 November 2021
Marketing authorisation
Vumerity in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Vumerity approved in European Union?
Yes. EMA authorised it on 15 November 2021.
Who is the marketing authorisation holder for Vumerity in European Union?
BIOGEN NETHERLANDS B.V. holds the EU marketing authorisation.